Oxford University Hospitals NHS Foundation Trust
Welcome,         Profile    Billing    Logout  
 315 Trials 
1301 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Middleton, Mark R
IGNYTE, NCT03767348 / 2016-004548-12: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Hourglass Jan 2024 - Mar 2024 : Data from IGNYTE trial in combination with Opdivo for 2L melanoma
Checkmark From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Nov 2020 - Nov 2020: From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Checkmark Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Nov 2019 - Nov 2019: Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Recruiting
2
340
Europe, US
RP1, nivolumab, Opdivo
Replimune Inc.
Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
11/24
11/24
TebeMRD, NCT05315258: Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Recruiting
2
850
Europe
Tebentafusp, IMCgp100
University of Oxford, Immunocore Ltd, Natera, Inc.
Melanoma (Skin), Melanoma, Uveal
06/25
06/26
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Recruiting
2
30
US
RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Replimune Inc., Roche Pharma AG
Hepatocellular Carcinoma
12/27
07/28
INJECTABL-1, NCT05688280: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

Recruiting
1/2
44
Europe, US
1.0% IP-001 for Injection, IP-001
Immunophotonics, Inc.
Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
05/25
05/25
PanDox, NCT04852367: Targeted Doxorubicin in Pancreatic Tumours

Withdrawn
1
18
Europe
Focused Ultrasound, Doxorubicin, ThermoDox
University of Oxford, National Institute for Health Research, United Kingdom, Imunon
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV, Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
03/23
03/23
NCT04735978: Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

Active, not recruiting
1
123
Europe, US
RP3, Nivolumab
Replimune Inc., Bristol-Myers Squibb
Advanced Solid Tumor
11/26
11/26
RP2-001-18, NCT04336241: Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Hourglass Oct 2021 - Dec 2021 : Updated data from trial in combination with RP2 for solid tumors
Checkmark From trial in combination with RP2 for solid tumors at ASCO 2021
Jun 2021 - Jun 2021: From trial in combination with RP2 for solid tumors at ASCO 2021
Recruiting
1
36
Europe
RP2, nivolumab, Opdivo
Replimune Inc.
Cancer
10/26
04/28
Fletcher, Simon
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
Exigency, NCT04723680: An Exploration of the Impact of Gene Therapy on the Lives of People With Haemophilia and Their Families

Completed
N/A
69
Europe
Qualitative interview
Haemnet, UniQure Biopharma B.V.
Hemophilia
02/23
02/23
NCT05315232: The Experiences of People Who Live With Glanzmanns Thrombasthenia.

Completed
N/A
122
Europe
survey and interview, diary completion
Haemnet, Hemab ApS
Glanzmann Thrombasthenia
04/23
04/23
NCT05314751: Learning to Live With Non-severe Haemophilia

Completed
N/A
165
Europe
Questionnaire and interview
Haemnet, BioMarin Pharmaceutical
Hemophilia
09/23
09/23
VWD 360, NCT06064643: The Lived Experience of People With Von Willebrand Disease

Recruiting
N/A
500
Europe
Online Survey, Qualitative Interview, Bleed Diary
Haemnet, Hemab ApS
Von Willebrand Diseases
12/24
12/24
Galloway, James C
NCT05890729: A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

Recruiting
1/2
94
Europe, US
XTMAB-16 or Placebo
Xentria, Inc.
Pulmonary Sarcoidosis
04/26
04/26
Winter, Stuart
AALL0434, NCT00408005: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Active, not recruiting
3
1895
Europe, Canada, US, RoW
Asparaginase, ASP-1, Asparaginase II, Asparaginase-E.Coli, Colaspase, Elspar, Kidrolase, L-Asnase, L-ASP, L-Asparaginase, L-Asparagine Amidohydrolase, Laspar, Lcf-ASP, Leucogen, Leunase, MK-965, Paronal, Re-82-TAD-15, Serasa, Spectrila, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Mercaptopurine, 3H-Purine-6-thiol, 6 MP, 6 Thiohypoxanthine, 6 Thiopurine, 6-Mercaptopurine, 6-Mercaptopurine Monohydrate, 6-MP, 6-Purinethiol, 6-Thiopurine, 6-Thioxopurine, 6H-Purine-6-thione, 1,7-dihydro- (9CI), 7-Mercapto-1,3,4,6-tetrazaindene, Alti-Mercaptopurine, Azathiopurine, Bw 57-323H, Flocofil, Ismipur, Leukerin, Leupurin, Mercaleukim, Mercaleukin, Mercaptina, Mercaptopurinum, Mercapurin, Mern, NCI-C04886, Puri-Nethol, Purimethol, Purine, 6-mercapto-, Purine-6-thiol (8CI), Purine-6-thiol, monohydrate, Purinethiol, Purinethol, U-4748, WR-2785, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Nelarabine, 2-Amino-6-methoxypurine arabinoside, 506U78, Arranon, Compound 506U78, GW506U78, Pegaspargase, L-Asparaginase with Polyethylene Glycol, Oncaspar, Oncaspar-IV, PEG-Asparaginase, PEG-L-Asparaginase, PEG-L-Asparaginase (Enzon - Kyowa Hakko), PEGLA, Polyethylene Glycol L-Asparaginase, Polyethylene Glycol-L-Asparaginase, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Thioguanine, 2-Amino 6MP, 2-Amino-1,7-dihydro-6H-purine-6-thione, 2-Amino-6-mercaptopurine, 2-Amino-6-purinethiol, 2-Aminopurin-6-thiol, 2-Aminopurine-6(1H)-thione, 2-Aminopurine-6-thiol, 2-Aminopurine-6-thiol Hemihydrate, 2-Mercapto-6-aminopurine, 6-Amino-2-mercaptopurine, 6-Mercapto-2-aminopurine, 6-Mercaptoguanine, 6-TG, 6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI), BW 5071, Lanvis, Tabloid, Thioguanine Hemihydrate, Thioguanine Hydrate, Tioguanin, Tioguanine, Wellcome U3B, WR-1141, X 27, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
09/17
03/25
PATHOS, NCT02215265 / 2014-003392-32: Post-operative Adjuvant Treatment for HPV-positive Tumours

Recruiting
3
1100
Europe, US, RoW
Cisplatin, Postoperative radiotherapy
Lisette Nixon, UNICANCER, AdventHealth, University of Leipzig, Princess Alexandra Hospital, Brisbane, Australia, Stanford University
Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
10/26
04/27
NCT02105545: Genome Sequencing of Human Cancer Tissues

Active, not recruiting
N/A
250
US
Cancer Treatment Options, treatment options, lifestyle changes, behavioral changes, genetics
New Mexico Cancer Care Alliance
Cancer
07/21
12/24
NCT05909020: EVEREST-HN 1: EVolution of a patiEnt-REported Symptom-based Risk Stratification sySTem

Recruiting
N/A
165
Europe
No intervention.
Royal Marsden NHS Foundation Trust, University of Leeds
Head and Neck Cancer
11/23
11/23
Cunningham, Chris
NCT02292641: Beyond TME Origins

Recruiting
N/A
383
Europe
New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery
Imperial College London, Pelican Cancer Foundation
Neoplasms, Adenocarcinoma, Carcinoma
12/26
12/31
Shen, Lin
TQB2450-III-08, NCT04809142: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer

Recruiting
3
392
RoW
TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection, Capecitabine tablets, Gemcitabine hydrochloride injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Biliary Cancer
03/22
02/23
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Terminated
3
5
RoW
Fluzoparib, SHR3162, Placebo
Jiangsu HengRui Medicine Co., Ltd.
Metastatic Pancreatic Cancer
02/22
02/22
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Recruiting
3
351
RoW
RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan
RemeGen Co., Ltd.
Gastric Cancer, HER2 Overexpressing Gastric Carcinoma
12/24
06/25
NCT04222114: Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis

Recruiting
3
282
RoW
Catumaxomab, The treatment of investigator choice
LintonPharm Co.,Ltd.
Stomach Neoplasms
03/23
08/23
NCT05015621: A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma

Recruiting
3
194
RoW
Surufatinib plus Toripalimab, HMPL-012 plus JS001, 5-fluorouracil, Calcium folinate and Irinotecan, FOLFIRI
Hutchison Medipharma Limited
Advanced Neuroendocrine Carcinoma
05/25
05/25
FG-M108-04, NCT06177041: M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Recruiting
3
486
RoW
M108 monoclonal antibody, Placebo, Oxaliplatin, Capecitabine
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
01/27
04/27
COMPASSIOn-15, NCT05008783: A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Active, not recruiting
3
610
RoW
AK104, Oxaliplatin, Capecitabine, Placebo
Akeso
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
08/24
04/25
NCT06304974: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Recruiting
3
488
RoW
BL-B01D1, Irinotecan, paclitaxel, docetaxel
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Esophageal Squamous Cell Carcinoma
05/26
05/26
NOTABLE-308, NCT06343116: Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer

Not yet recruiting
3
420
NA
Nimotuzumab injection, Taixinsheng, Placebo, Trifluridine/tipiracil
Biotech Pharmaceutical Co., Ltd.
Refractory Metastatic Colorectal Cancer
04/27
04/27
NCT05352516: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

Completed
3
514
RoW
HLX14, Prolia®
Shanghai Henlius Biotech
Postmenopausal
12/23
07/24
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
12/24
07/25
AK109-301, NCT06341335: A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
3
506
RoW
cadonilimab, AK104, pulocimab, AK109, paclitaxel, placebo
Akeso
Gastric and Gastroesophageal Junction Adenocarcinoma
11/26
07/27
G-HOPE-001, NCT06238843: A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma

Enrolling by invitation
3
450
RoW
irinotecan, IBI343, paclitaxel
Innovent Biologics (Suzhou) Co. Ltd.
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
12/26
12/27
HLX22-GC-301, NCT06532006: A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Not yet recruiting
3
550
RoW
HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine
Shanghai Henlius Biotech
Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
06/27
09/28
NCT04233151: QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety

Recruiting
3
590
RoW
QL1203, Placebo, mFOLFOX6 regimen
Qilu Pharmaceutical Co., Ltd.
Metastatic Colorectal Cancer
12/24
07/25
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Recruiting
3
680
RoW
JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy
Shanghai Junshi Bioscience Co., Ltd.
Gastric or Esophagogastric Junction Adenocarcinoma
03/26
07/28
NCT06086457: PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

Recruiting
3
436
RoW
Radiation, Modern intensity modulated radiotherapy, TP or PF regimen depended on investigator's choice., Chemotherapy, PD-1 inhibitor, Camrelizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking University Cancer Hospital & Institute, Beijing Cancer Prevention & Treatment Society, Hebei Medical University Fourth Hospital, Tianjin Medical University Cancer Institute and Hospital, Fujian Cancer Hospital, Anyang Tumor Hospital, The First Affiliated Hospital with Nanjing Medical University, Sichuan Cancer Hospital and Research Institute, Tengzhou Central People's Hospital, The First Affiliated Hospital of Xiamen University, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital Xi'an Jiaotong University, Second Affiliated Hospital of Xi'an Jiaotong University, Affiliated Hospital of North Sichuan Medical College, Changzhou Cancer Hospital of Soochow University, Henan Cancer Hospital
Esophageal Neoplasms
06/26
08/29
TQB3454-III-01, NCT05987358: A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.

Not yet recruiting
3
165
RoW
TQB3454 tablets, TQB3454 tablets matching placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Biliary Carcinoma
12/26
12/26
NCT04848753: Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Active, not recruiting
3
663
RoW
Toripalimab combined with cisplatin and paclitaxel, Placebo combined with cisplatin and paclitaxel
Shanghai Junshi Bioscience Co., Ltd.
Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
05/27
05/27
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
NCT03992911: Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma

Recruiting
2/3
336
RoW
Simmtecan, 5-FU and l-LV, FOLFSIM regimen, Toripalimab, JS001, Etoposide, Cisplatin, EP regimen, Etoposide, Carboplatin, EC regimen
Peking University
Neuroendocrine Carcinoma of the Bladder
06/22
06/23
NCT06221748: DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Recruiting
2/3
90
RoW
Disitamab Vedotin Injection, DV,RC48, Cadonilimab Injection, AK104, Cadonilimab Injection, Paclitaxel Injection
RemeGen Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
12/26
12/27
NCT05980481: A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Recruiting
2/3
130
RoW
RC48-ADC, Disitamab Vedotin, Trastuzumab Injection, Trastuzumab, Toripalimab, JS001, Oxaliplatin injection, Oxaliplatin, Capecitabine, Capecitabine Tablets
RemeGen Co., Ltd.
Gastric Cancer
07/24
07/25
NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations

Checkmark NMPA cleared CTA to conduct the Phase 2a trial for metastatic gastric cancer or GE junction adenocarcinoma with FGFR2 gene amplification
Dec 2020 - Dec 2020: NMPA cleared CTA to conduct the Phase 2a trial for metastatic gastric cancer or GE junction adenocarcinoma with FGFR2 gene amplification
Recruiting
2a
80
RoW
Infigratinib, BGJ398
LianBio LLC
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor
12/22
12/23
NCT03567629: Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer

Active, not recruiting
2
130
RoW
Irinotecan, fluorouracil / calcium folinate, Capecitabine, S1, Bevacizumab, Cetuximab, Oxaliplatin
Peking University, Liaoning Tumor Hospital & Institute, Zhejiang University
mCRC
12/21
12/23
NCT04705519: Nab-paclitaxel Combined With Bevacizumab in the Treatment of Metastatic Neuroendocrine Carcinoma

Recruiting
2
100
RoW
Nab-paclitaxel Combined With Bevacizumab
Peking University, Qilu Pharmaceutical Co., Ltd.
Neuroendocrine Carcinoma
01/22
01/24
SEARCH-01, NCT04521179: Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors

Completed
2
102
RoW
KN026 combination, IO therapy
Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Peking University
HER2-positive Solid Tumors
01/22
05/23
NCT04880811: Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Not yet recruiting
2
43
RoW
Afatinib, Toripalimab
Peking University
Esophageal Squamous Cell Carcinoma
10/22
05/23
2019-012-00CH1, NCT04169672: Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Completed
2
248
RoW
Surufatinib, HMPL-012, Toripalimab, JS001
Hutchison Medipharma Limited
Advanced Solid Tumors
02/23
02/23
NCT04723030: The Transformation of Locally Advanced Pancreatic Cancer.

Not yet recruiting
2
30
RoW
carleilizumab+apathy mesylate+radiotherapy+paclitaxel (albumin-bound)
Peking University
Locally Advanced Pancreatic Cancer
04/23
04/23
NCT05030246: Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer

Recruiting
2
72
RoW
Surufatinib/Toripalimab, HMPL-012/JS001
Peking University
Refractory Metastatic Digestive System Carcinoma, Primary Peritoneal Cancer
04/23
07/23
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Terminated
2
6
RoW
Infigratinib, BGJ398, BBP-831
LianBio LLC
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
05/24
05/24
NCT05386056: Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Not yet recruiting
2
54
RoW
Pembrolizumab, MK-3475, Sinoporphyrin Sodium, DVDMS, Photodynamic therapy, PDT
Peking University
Esophageal Squamous Cell Carcinoma
10/23
06/24
NCT05022654: SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

Recruiting
2
40
RoW
SI-B001, Irinotecan
Sichuan Baili Pharmaceutical Co., Ltd.
Esophageal Squamous Cell Carcinomas
06/25
06/25
NCT03667170: KN035 for dMMR/MSI-H Advanced Solid Tumors

Recruiting
2
200
RoW
KN035
3D Medicines (Sichuan) Co., Ltd.
Solid Tumor
12/24
12/25
NCT06222944: Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Not yet recruiting
2
90
RoW
Anlotinib, Anlotinib Hydrochloride Capsule, TQB2450, Albumin-Bound Paclitaxel, Paclitaxel (albumin-bound), Paclitaxel for injection(Albumin Bound)
Peking University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gastric Cancer, Adenocarcinoma of Esophagogastric Junction
08/25
08/26
NCT05165407: Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC

Recruiting
2
40
RoW
Sintilimab, IBI310, Surufatinib, HMPL-012
Peking University
Neuroendocrine Neoplasm
03/24
03/25
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

Active, not recruiting
2
103
RoW
Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan
Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany
BRAF V600E, Metastatic Colorectal Cancer
12/23
01/25
NCT04891198: ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors

Recruiting
2
126
RoW
Envafolimab
3D Medicines (Sichuan) Co., Ltd.
Solid Tumor
08/27
04/28
NCT05866510: Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer

Recruiting
2
47
RoW
Utidelone and anlotinib
Peking University, Beijing Biostar Pharmaceuticals Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Esophageal Cancer
04/24
04/24
QLS31905-202, NCT06446388: Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Not yet recruiting
2
360
RoW
QLS31905, Oxaliplatin, Capecitabine, Gemcitabine, Cisplatin, QL1706, Chemotherapy drug
Qilu Pharmaceutical Co., Ltd.
Advanced Solid Tumor
06/26
12/27
CGOG-IMAGINE-06, NCT06580574: Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

Recruiting
2
38
RoW
PD1/PDL1 antibody monotherapy, up to 24 weeks, Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks, Radical surgery
Peking University
Gastric Cancer, Colon Cancer, MSI-H, DMMR Cancer
06/29
06/29
NCT05628857: A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor

Recruiting
2
240
RoW
RC108
RemeGen Co., Ltd.
Digestive Cancer
10/24
10/25
NCT05818982: To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC

Recruiting
2
72
RoW
Afatinib, Irinotecan
Peking University
Advanced Esophageal Squamous Cell Carcinoma
02/25
02/26
NCT04923932: Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients

Checkmark Initiated P2 trial for advanced/metastatic MET amplified gastric cancer or adenocarcinoma of the gastroesophageal junction
Jul 2021 - Jul 2021: Initiated P2 trial for advanced/metastatic MET amplified gastric cancer or adenocarcinoma of the gastroesophageal junction
Recruiting
2
75
RoW
Savolitinib, hmpl-504
Hutchison Medipharma Limited
Gastric Cancer, Esophagogastric Junction Disorder
04/25
10/25
NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor

Recruiting
2
50
RoW
TT-00420 (tinengotinib)
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma Metastatic
06/25
10/25
NCT06008054: A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

Recruiting
2
376
RoW
SI-B003, BL-B01D1, PD-1 Monoclonal Antibody
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Esophageal Cancer, Gastric Cancer, Colorectal Cancer
12/25
12/25
EVER-132-003, NCT05119907: Study of Sacituzumab Govitecan in Patients With Solid Tumor

Recruiting
2
300
RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132
Gilead Sciences
Solid Tumor
12/25
12/25
RATIONALE-209, NCT03736889: Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Recruiting
2
200
RoW
Tislelizumab (BGB-A317)
BeiGene
MSI-H/dMMR Solid Tumors
11/26
09/27
HERCKER-01, NCT05985707: KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

Not yet recruiting
2
80
RoW
KN026, KN046, XELOX
Peking University Cancer Hospital & Institute
HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer
12/26
12/26
NCT06099821: KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Recruiting
2
39
RoW
KN046, Regorafenib, Apatinib
Peking University Cancer Hospital & Institute
Digestive System Cancers
12/26
12/26
NCT05985109: KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

Recruiting
2
98
RoW
KN046, regorafenib
Peking University Cancer Hospital & Institute
Colorectal Cancer
12/26
12/26
CS3007-101, NCT04254939: A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor

Checkmark Preliminary results from a bridging study in Chinese Patients with Unresectable or Metastatic GIST
Sep 2020 - Sep 2020: Preliminary results from a bridging study in Chinese Patients with Unresectable or Metastatic GIST
Checkmark Partial results from P1/2 bridging study in Chinese patients with unresectable or metastatic GIST at ASCO 2020
May 2020 - May 2020: Partial results from P1/2 bridging study in Chinese patients with unresectable or metastatic GIST at ASCO 2020
Completed
1/2
65
RoW
CS3007 (BLU-285)
CStone Pharmaceuticals, Blueprint Medicines Corporation
Gastrointestinal Stromal Tumors
04/20
04/23
NCT03565003: A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China

Completed
1/2
126
RoW
JAB-3068
Jacobio Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
01/23
01/23
NCT04988191: Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer

Recruiting
1/2
44
RoW
Toripalimab, Bevacizumab, Irinotecan
Peking University
Colorectal Carcinoma
06/23
12/23
AK109-201, NCT04982276: A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Recruiting
1/2
138
RoW
AK109, paclitaxel, AK104
Akeso
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
10/25
01/27
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Recruiting
1/2
114
RoW
TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer
09/24
12/24
NCT05139082: Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System Tumors

Not yet recruiting
1/2
60
RoW
TQB3616 capsules＋ TQB2450 injection
Peking University
Digestive System Tumors
10/23
10/23
PM8002-A001, NCT05918445: PM8002 in the Treatment of Patients With Advanced Solid Tumors

Recruiting
1/2
380
RoW
PM8002
Biotheus Inc.
Malignant Neoplasm
11/25
11/25
NCT06157827: A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

Recruiting
1/2
178
RoW
LBL-024 for Injection, LBL-024, Etoposide Injection, Etoposide, Carboplatin Injection, Carboplatin, Atezolizumab injection, Atezolizumab, Cisplatin injection, Cisplatin
Nanjing Leads Biolabs Co.,Ltd
Advanced Neuroendocrine Carcinoma
11/26
07/27
ORIN1001-C1, NCT05154201: Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.

Active, not recruiting
1/2
350
RoW
ORIN1001
Orinove, Inc., Fosun Pharma
Effect of Drug
12/24
12/24
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Recruiting
1/2
320
RoW
TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab
Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb
Advanced Cancer
02/25
05/25
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853

Recruiting
1/2
254
US, RoW
HH2853 Tablets
Haihe Biopharma Co., Ltd.
FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
12/25
12/25
NCT06464055: A Study of GQ1010 in Subjects With Advanced Solid Tumors

Recruiting
1/2
220
RoW
Dose Escalation, Dose Expansion1, Dose Expansion2, phase II
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Advanced Malignant Solid Tumors
05/28
12/28
NCT06378593: A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

Recruiting
1/2
130
RoW
3HP-2827
3H (Suzhou) Pharmaceuticals Co., Ltd.
Solid Tumors With FGFR2 Alterations, Adult
06/28
06/28
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Recruiting
1/2
192
RoW
CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC)
CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University
Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
06/24
06/38
LBL-024-CN001, NCT05170958: A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors

Recruiting
1/2
396
RoW
LBL-024 for Injection, LBL-024
Nanjing Leads Biolabs Co.,Ltd
Advanced Solid Tumor
12/26
12/26
NCT05176665: EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

Recruiting
1/2
152
US, RoW
EMB-01, FIT-013a
Shanghai EpimAb Biotherapeutics Co., Ltd., Labcorp Corporation of America Holdings, Inc
Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor
12/25
12/25
NCT05964543: The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors

Recruiting
1/2
72
RoW
Q-1802 Injection,Oxaliplatin Injection,Capecitabine, Q-1802,Oxaliplatin Injection,Xeloda
QureBio Ltd.
Gastroesophageal Junction (GEJ) Adenocarcinoma
08/24
08/25
NCT05383482: Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Active, not recruiting
1/2
22
RoW
Afuresertib, LAE002, Nab paclitaxel, Docetaxel, Sintilimab
Laekna Limited
Solid Tumor, NSCLC, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gastric and Gastroesophageal Junction Adenocarcinoma
06/24
12/25
NCT05508659: A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors

Not yet recruiting
1/2
128
NA
Duvelisib, COPIKTRA, SG001, Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Solid Tumors
09/24
03/25
NCT05315167: A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Recruiting
1/2
267
RoW
PRJ1-3024
Zhuhai Yufan Biotechnologies Co., Ltd
Advanced Solid Tumor, Advanced Solid Malignancies
11/24
03/25
NCT04632108: A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
214
RoW
ASKB589 Injection
Jiangsu Aosaikang Pharmaceutical Co., Ltd., Jiangsu Aosaikang Biomedicine Co. LTD.
Malignant Solid Tumor
12/24
12/25
JSKN003-102, NCT05744427: To Evaluate the Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors

Recruiting
1/2
300
RoW
JSKN003
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Solid Tumor
12/24
12/25
NCT05830097: A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

Recruiting
1/2
260
US, RoW
CBP-1019, CBP-1019 for injection
Coherent Biopharma (Hefei) Co., Ltd.
Cancer, Breast, Cancer, Lung, Cancer of Pancreas, Cancer of Esophagus, Cancer Colorectal
06/25
09/25
NCT05518045: Study of LM-108 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Enrolling by invitation
1/2
392
RoW
LM-108, Toripalimab
LaNova Medicines Limited
Advanced Solid Tumor
07/25
10/25
Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Recruiting
1/2
374
Europe, Canada, Japan, US, RoW
Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil
Takeda, Takeda Development Center Americas, Inc. (TDC Americas)
Solid Neoplasms
01/26
01/26
NCT06008925: Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

Recruiting
1/2
43
RoW
Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), VG161, Nivolumab Injection, OPDIVO
CNBG-Virogin Biotech (Shanghai) Ltd.
Metastatic Gastric Cancer
12/25
06/26
NCT05167448: A Study of ES104 in Patients With Metastatic Colorectal Cancer

Active, not recruiting
1/2
58
RoW
ES104
Elpiscience (Suzhou) Biopharma, Ltd.
Metastatic Colorectal Cancer
05/26
07/26
SHR-A1811-208, NCT06015048: A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

Recruiting
1/2
364
RoW
SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapies
Jiangsu HengRui Medicine Co., Ltd.
HER2-expressing Advanced Solid Tumors
11/26
12/26
CT041-CG4006, NCT03874897: Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Completed
1
134
RoW
CAR-CLDN18.2 T-Cells, Chimeric Antigen Receptor T Cells Targeting Claudin18.2, PD-1 Monoclonal Antibody, Toripalimab, Chemotherapy
Peking University, CARsgen Therapeutics Co., Ltd.
Advanced Solid Tumor
03/21
01/24
 

Download Options